Agios Pharmaceuticals Inc. | Small-cap | Healthcare
$32.71
-2.12%
| Agios Stock Comparison:
Agios vs VertexAgios vs RegeneronAgios vs Vera TherapeuticsAgios vs Immunocore HoldingsAgios vs Amicus TherapeuticsAgios vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 36.5M
Gross Profit 32.3M 88.59%
Operating Income -425.7M -1,166.47%
Net Income 673.7M 1,845.92%
EPS (Diluted) $11.64

Balance Sheet Metrics

Total Assets 1.7B
Total Liabilities 122.2M
Shareholders Equity 1.5B
Debt to Equity 0.08

Cash Flow Metrics

Operating Cash Flow -173.9M
Free Cash Flow -391.5M

Revenue & Profitability Trend

Agios Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 36.5M 26.8M 14.2M 0 0
Cost of Goods Sold 4.2M 2.9M 1.7M 0 2.8M
Gross Profit 32.3M 23.9M 12.5M 0 200.4M
Operating Expenses 458.1M 415.4M 401.6M 378.4M 335.9M
Operating Income -425.7M -391.5M -389.0M -378.4M -335.9M
Pre-tax Income 718.0M -352.1M -231.8M -356.5M -329.3M
Income Tax 44.2M - - - -
Net Income 673.7M -352.1M -231.8M 1.6B -327.4M
EPS (Diluted) $11.64 -$6.33 -$4.23 $26.55 -$4.74

Income Statement Trend

Agios Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 965.6M 833.8M 832.8M 1.1B 636.7M
Non-Current Assets 697.6M 103.3M 405.9M 373.5M 216.3M
Total Assets 1.7B 937.1M 1.2B 1.4B 853.0M
Liabilities
Current Liabilities 81.2M 68.0M 62.6M 59.8M 94.4M
Non-Current Liabilities 41.1M 58.1M 75.3M 85.9M 359.1M
Total Liabilities 122.2M 126.1M 137.9M 145.8M 453.5M
Equity
Total Shareholders Equity 1.5B 811.0M 1.1B 1.3B 399.5M

Balance Sheet Composition

Agios Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 673.7M -352.1M -231.8M -356.5M -329.3M
Operating Cash Flow -173.9M -308.2M -306.4M -294.3M -322.6M
Investing Activities
Capital Expenditures -1.6M 326.0K -3.9M -5.7M -14.1M
Investing Cash Flow 363.4M 257.1M 375.0M -554.2M 76.5M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 0 0 -331.0K -803.1M 250.2M
Free Cash Flow -391.5M -314.6M -314.4M -413.1M -304.9M

Cash Flow Trend

Agios Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 2.89
Forward P/E -5.48
Price to Book 1.32
Price to Sales 52.14
PEG Ratio -5.48

Profitability Ratios

Profit Margin 1,798.26%
Operating Margin -1,221.97%
Return on Equity 60.26%
Return on Assets -22.88%

Financial Health

Current Ratio 18.50
Debt to Equity 3.61
Beta 0.73

Per Share Data

EPS (TTM) $11.54
Book Value per Share $25.33
Revenue per Share $0.65

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
agio 1.9B 2.89 1.32 60.26% 1,798.26% 3.61
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Vera Therapeutics 1.4B -8.41 2.58 -39.49% 0.00% 10.18
Immunocore Holdings 1.6B -31.41 4.13 -5.86% -6.48% 114.67
Amicus Therapeutics 1.8B -31.56 9.08 -18.12% -5.41% 229.11

Financial data is updated regularly. All figures are in the company's reporting currency.